Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Trimebutine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimebutine SCHEMBL25705 | 0.90 | OPRM1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL14273976 | 0.90 | OPRM1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL7428847 | 0.89 | OPRM1 (0.98) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL28274910 | 0.85 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL67225 | 0.85 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL5011979 | 0.85 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| Trimebutine SCHEMBL1652810 | 0.85 | ALDH1A1 (1.00) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL16522145 | 0.84 | OPRM1 (0.88) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL14317655 | 0.82 | OPRM1 (0.83) | OPRM1OPRD1PDE4DNR1I2CHRM2 | |
| SCHEMBL23977102 | 0.81 | OPRM1 (0.81) | OPRM1OPRD1PDE4DNR1I2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-1861377-B1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1994011-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1861377-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007102059-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2007-09-13 | — | — | WO | disclosed |
| EP-1809607-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006097808-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006048754-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | TRPV1, CNR2, CNR1 | OPRM1 403/4885OPRD1 294/4885PDE4D 1886/4885 |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | CNR1, CNR2, NPSR1 | OPRM1 20/4885OPRD1 11/4885PDE4D 1538/4885 |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | OPRM1 305/4885OPRD1 115/4885PDE4D 2497/4885 |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | OPRM1 312/4885OPRD1 140/4885PDE4D 2868/4885 |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | OPRM1 740/4885OPRD1 361/4885PDE4D 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.